With only a few months of cash left, and no good way to raise more, one would think the Nic-meister has finally found religion. Trying to raise money by any other approach than a partnership will likely result in the financing entity getting over 50% ownership of PYMX, and then the new majority owner would probably fire Nic.
So a broad pharma partnership is the logical way forward. PYMX has very little bargaining leverage, but there might be a couple interested pharmas bidding against eachother, so that is the best hope for shareholders.
But however logical a broad pharma partnership sounds, the severe stock price collapse suggests that Nic is instead trying to do a financing, and the financing entity is driving the pps down to get a better deal.
I guess we'll find out soon enough. Personally I don't have a position (lost some $$ on it earlier this year), but am watching the stock mainly for its 'entertainment' value. The company's science is extremely cool, so it's worth keeping an eye on. I never thought it would ever get this cheap, and it seems like a potential speculative play for a rebound. Either that or it goes to zero. Will see what happens.